Skip to main content
Premium Trial:

Request an Annual Quote

Cellexus Ltd. Acquires Cellexus Biosystems IP, Assets

NEW YORK (GenomeWeb News) – The investors in Cellexus Ltd. said yesterday that they have acquired the assets of Cellexus Biosystems Plc and have formed a new management team aimed at bringing the firm’s products to market.
 
Cellexus makes single-use bioreactors and cell-based technologies for biopharmaceutical research and production. The firm said that since the asset acquisition it has “made significant design and operational improvements to the CellMaker bioreactor systems.”
 
It also intends to launch a range of new products over the coming months including the CellMaker Regular for culture of E. Coli and Pichia cells and the CellMaker PLUS for culture of all cells including mammalian and insect.  
 
The Cambridgeshire, UK-based company said that it made the purchase in April, but did not disclose it until this week.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.